Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 145.72
EXAS's Cash to Debt is ranked higher than
74% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. EXAS: 145.72 )
EXAS' s 10-Year Cash to Debt Range
Min: 12.24   Max: No Debt
Current: 145.72

F-Score: 2
Z-Score: 66.48
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -3390.62
EXAS's Operating margin (%) is ranked higher than
54% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.88 vs. EXAS: -3390.62 )
EXAS' s 10-Year Operating margin (%) Range
Min: -51374.51   Max: 1150.29
Current: -3390.62

-51374.51
1150.29
Net-margin (%) -3372.36
EXAS's Net-margin (%) is ranked higher than
53% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. EXAS: -3372.36 )
EXAS' s 10-Year Net-margin (%) Range
Min: -46049.02   Max: 1123.53
Current: -3372.36

-46049.02
1123.53
ROE (%) -46.38
EXAS's ROE (%) is ranked higher than
70% of the 1143 Companies
in the Global Biotechnology industry.

( Industry Median: -35.75 vs. EXAS: -46.38 )
EXAS' s 10-Year ROE (%) Range
Min: -505.37   Max: -26.92
Current: -46.38

-505.37
-26.92
ROA (%) -43.05
EXAS's ROA (%) is ranked higher than
66% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. EXAS: -43.05 )
EXAS' s 10-Year ROA (%) Range
Min: -95.07   Max: -18.9
Current: -43.05

-95.07
-18.9
ROC (Joel Greenblatt) (%) -584.33
EXAS's ROC (Joel Greenblatt) (%) is ranked higher than
72% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. EXAS: -584.33 )
EXAS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3463.3   Max: -641.7
Current: -584.33

-3463.3
-641.7
Revenue Growth (%) -22.70
EXAS's Revenue Growth (%) is ranked higher than
67% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. EXAS: -22.70 )
EXAS' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 47.4
Current: -22.7

0
47.4
EBITDA Growth (%) 33.80
EXAS's EBITDA Growth (%) is ranked higher than
95% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. EXAS: 33.80 )
EXAS' s 10-Year EBITDA Growth (%) Range
Min: -39.4   Max: 45.4
Current: 33.8

-39.4
45.4
EPS Growth (%) 33.50
EXAS's EPS Growth (%) is ranked higher than
94% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. EXAS: 33.50 )
EXAS' s 10-Year EPS Growth (%) Range
Min: -43.1   Max: 46.5
Current: 33.5

-43.1
46.5
» EXAS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

EXAS Guru Trades in Q2 2013

RS Investment Management Sold Out
Tom Russo Sold Out
» More
Q1 2014

EXAS Guru Trades in Q1 2014

Paul Tudor Jones 11,040 sh (New)
George Soros 200,000 sh (New)
» More
Q2 2014

EXAS Guru Trades in Q2 2014

Chase Coleman 2,000,000 sh (New)
PRIMECAP Management 2,491,300 sh (New)
Louis Moore Bacon 100,000 sh (unchged)
Paul Tudor Jones Sold Out
George Soros Sold Out
» More
Q3 2014

EXAS Guru Trades in Q3 2014

Steven Cohen 468,200 sh (New)
Paul Tudor Jones 18,511 sh (New)
PRIMECAP Management 2,496,300 sh (+0.2%)
Chase Coleman Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with EXAS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
PRIMECAP Management 2014-06-30 New Buy0.05%$11.17 - $17.27 $ 25.9789%2491300
George Soros 2014-06-30 Sold Out 0.03%$11.17 - $17.27 $ 25.9789%0
George Soros 2014-03-31 New Buy0.03%$11.75 - $14.82 $ 25.9793%200000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Exact Sciences Corp

Meridian Funds Comments on Exact Sciences Corp - Jun 20, 2014

Exact Sciences Corp. (EXAS) also had negative returns during the period, which created a drag on overall Fund performance. Exact Sciences is an early stage diagnostic company with a test for early detection of colorectal cancers. Upon receipt of the U.S. Food and Drug Administration’s approval, we believe that Exact Sciences’s Cologuard test will help revolutionize colorectal screening and increase overall compliance rates with clinical guidelines. We think that the large market, combined with attractive unit economics, should drive an improvement in shareholder value.



From Meridian Funds's semi-annual report ended December 31, 2013.



Check out Meridian Funds latest stock trades

Top Ranked Articles about Exact Sciences Corp

Weekly CEO Sells Highlight: Exact Sciences Corp Zayo Group Holdings Inc, Western Alliance Bancorp, and Envision Healthcare Holdings Inc.
According to GuruFocus Insider Data, these are the largest CEO sales during the past week: Exact Sciences Corp Zayo Group Holdings Inc, Western Alliance Bancorp, and Envision Healthcare Holdings Inc. Read more...
Meridian Funds Comments on Exact Sciences Corp
Exact Sciences Corp. (EXAS) also had negative returns during the period, which created a drag on overall Fund performance. Exact Sciences is an early stage diagnostic company with a test for early detection of colorectal cancers. Upon receipt of the U.S. Food and Drug Administration’s approval, we believe that Exact Sciences’s Cologuard test will help revolutionize colorectal screening and increase overall compliance rates with clinical guidelines. We think that the large market, combined with attractive unit economics, should drive an improvement in shareholder value. Read more...

Ratios

vs
industry
vs
history
P/B 10.10
EXAS's P/B is ranked higher than
65% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 6.13 vs. EXAS: 10.10 )
EXAS' s 10-Year P/B Range
Min: 1.49   Max: 37
Current: 10.1

1.49
37
P/S 2642.00
EXAS's P/S is ranked higher than
65% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 28.86 vs. EXAS: 2642.00 )
EXAS' s 10-Year P/S Range
Min: 8.84   Max: 2806
Current: 2642

8.84
2806
EV-to-EBIT -25.39
EXAS's EV-to-EBIT is ranked higher than
66% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. EXAS: -25.39 )
EXAS' s 10-Year EV-to-EBIT Range
Min: -32.7   Max: -0.2
Current: -25.39

-32.7
-0.2
Current Ratio 12.91
EXAS's Current Ratio is ranked higher than
91% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. EXAS: 12.91 )
EXAS' s 10-Year Current Ratio Range
Min: 1.02   Max: 50.84
Current: 12.91

1.02
50.84
Quick Ratio 12.75
EXAS's Quick Ratio is ranked higher than
91% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. EXAS: 12.75 )
EXAS' s 10-Year Quick Ratio Range
Min: 1.02   Max: 50.84
Current: 12.75

1.02
50.84

Valuation & Return

vs
industry
vs
history
Price/Net Cash 11.60
EXAS's Price/Net Cash is ranked higher than
81% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 50.00 vs. EXAS: 11.60 )
EXAS' s 10-Year Price/Net Cash Range
Min: 2.02   Max: 90
Current: 11.6

2.02
90
Price/Net Current Asset Value 11.49
EXAS's Price/Net Current Asset Value is ranked higher than
80% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 29.38 vs. EXAS: 11.49 )
EXAS' s 10-Year Price/Net Current Asset Value Range
Min: 2.02   Max: 90
Current: 11.49

2.02
90
Price/Tangible Book 10.29
EXAS's Price/Tangible Book is ranked higher than
70% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9.38 vs. EXAS: 10.29 )
EXAS' s 10-Year Price/Tangible Book Range
Min: 1.88   Max: 34.23
Current: 10.29

1.88
34.23
Price/Median PS Value 62.02
EXAS's Price/Median PS Value is ranked higher than
66% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. EXAS: 62.02 )
EXAS' s 10-Year Price/Median PS Value Range
Min: 0.25   Max: 45.07
Current: 62.02

0.25
45.07
Earnings Yield (Greenblatt) -4.00
EXAS's Earnings Yield (Greenblatt) is ranked higher than
78% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. EXAS: -4.00 )
EXAS' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -4

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:EXK.Germany,
Exact Sciences Corp was incorporated in the State of Delaware on February 10, 1995. The company is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The Company's Cologuard test is designed to detect pre-cancerous lesions or polyps, and each of the four stages of colorectal cancer and is expected to be a powerful, preventive tool. By detecting pre-cancers and cancers early with its test, affected patients can be referred to colonoscopy, during which the polyps or lesions can be removed. In November 2012, Company completed enrollment for its pivotal FDA clinical trial with over 10,000 patients enrolled at 90 enrollment sites in the U.S. and Canada. All patients provided a sample to be tested with Cologuard test, and received a FIT test and a colonoscopy. As of December 31, 2013, Company owned 10 issued patents and 28 pending patent applications in the United States, and 62 issued patents and 26 pending patent applications in foreign jurisdictions. In addition, as part of its 2009 strategic transaction with Genzyme Corporation, it received an exclusive license back from Genzyme Corporation in the fields of colorectal cancer screening and stool-based detection of any disease or condition to the 26 patents issued and 7 pending patent applications in the U.S., and 29 patents issued and 12 pending patent applications in foreign jurisdictions sold to Genzyme. Certain of its activities are subject to regulatory oversight by the FDA under provisions of the Federal Food, Drug, and Cosmetic Act and regulations thereunder, including regulations governing the development, marketing, labeling, promotion, manufacturing and export of diagnostic products. sDNA testing faces competition from procedure-based detection technologies such as flexible sigmoidoscopy, colonoscopy and virtual colonoscopy.
» More Articles for EXAS

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Exact Sciences Corp Zayo Group Holdings Inc, Western Alliance Bancorp, a Oct 27 2014 
CEO Kevin T. Conroy of Exact Sciences to Be Interviewed Live on Clear Channel -- iHeart Business Tal Oct 15 2014 
Meridian Funds Comments on Exact Sciences Corp Jun 20 2014 
comment on EXAS May 12 2013 
comment on EXAS May 12 2013 
comment on EXAS May 12 2013 
Weekly CEO Buys Highlight: BFS, FL, BGC, AMCF, and EXAS Nov 28 2010 
EXACT Sciences Corp. (EXAS) CEO Kevin T Conroy buys 6,000 Shares Nov 23 2010 
EXACT Sciences Corp. (EXAS) CFO Maneesh Arora buys 2,500 Shares Aug 20 2010 
cooldecency99 note on EXAS May 01 2010 

More From Other Websites
Exact Sciences Addresses CMS Reimbursement for Cologuard® Dec 19 2014
EXACT SCIENCES CORP Files SEC form 8-K, Entry into a Material Definitive Agreement Dec 18 2014
Exact Sciences Announces Pricing of Public Offering of Common Stock Dec 16 2014
Exact Sciences Announces Agreement to Sell 4,000,000 Common Shares Dec 15 2014
Exact Sciences Announces Mercy Hospital St. Louis Now Offering Cologuard® Dec 02 2014
Equity markets end lower, though commodity prices staged a huge “squeeze” higher... Dec 01 2014
Exact Sciences Announces Final Payment Decision for Cologuard® from the Centers for Medicare &... Nov 25 2014
Cologuard® Wins Popular Science Magazine’s 2014 “Best of What's New” Award Nov 12 2014
EXACT SCIENCES CORP Financials Nov 06 2014
American Cancer Society Includes Exact Sciences' Cologuard in Colorectal Cancer Prevention and Early... Nov 06 2014
American Cancer Society Includes Exact Sciences’ Cologuard in Colorectal Cancer Prevention and... Nov 06 2014
Exact Sciences to Participate in November Conferences Nov 05 2014
Exact Sciences to Participate in November Conferences Nov 05 2014
10-Q for EXACT Sciences Corp. Nov 03 2014
EXACT SCIENCES CORP Files SEC form 10-Q, Quarterly Report Oct 31 2014
Exact Sciences Announces Meriter-UnityPoint Health Now Offering Cologuard® Oct 29 2014
Exact Sciences Announces Meriter-UnityPoint Health Now Offering Cologuard® Oct 29 2014
Weekly CEO Sells Highlight: Exact Sciences Corp Zayo Group Holdings Inc, Western Alliance ... Oct 27 2014
Exact Sciences Reports Third-Quarter 2014 Financial Results Oct 27 2014
Exact Sciences misses 3Q profit forecasts Oct 27 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK